Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days

Cancer Science

Volumn 96, Issue 10, 2005, Pages 721-728

  Yamada, Yasuhide ^a   Yamamoto, Noboru ^a   Shimoyama, Tatsu ^a   Horiike, Atsushi ^a   Fujisaka, Yasuhito ^a   Takayama, Kyoko ^a   Sakamoto, Terumi ^a   Nishioka, Yuki ^b   Yasuda, Sanae ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; INDISULAM;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; ILEUS; INJECTION SITE REACTION; LEUKOPENIA; LIPOSARCOMA; LIVER TOXICITY; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; NEUTROPENIA; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; WILD TYPE;

ADULT; AGED; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASMS; POLYMORPHISM, GENETIC; SULFONAMIDES;

EID: 28444465958     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00109.x     Document Type: Article

References (18)

1. Fukuoka K, Usuda J, Iwamoto Y et al. Mechanism of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 2001; 19: 219-27.
2. Sugi N, Ozawa Y, Watanabe T et al. A novel agent ER-35744, targeting G1 phase. II: Antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 1996; 37: A2668.
3. Yokoi A, Kuromitsu J, Kawai T et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 2002; 1: 275-86.
4. Ozawa Y, Sugi NH, Nagasu T et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 2001; 37: 2275-82.
5. Raymond E, ten Bokkel Huinink WW, Taieb J et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002; 20: 3508-21.
6. Punt CJ, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Phase I and pharmacokinetic, study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol 2001; 12: 1289-93.
7. Dittrich C, Dumez H, Calvert H et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 2003; 9: 5195-204.
8. Terret C, Zanetta S, Roche H et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003; 39: 1097-104.
9. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-90.
10. Van den Bongard HJGD, Sparidans RW, Critchley DJP, Beijnen JH, Schellens JHM. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Invest New Drugs 2004; 22: 151-8.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
12. Owa T, Yoshino H, Okauchi T et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 1999; 42: 3789-99.
13. Rigas JR, Tong WP, Kris MG, Orazem JP, Young CW, Warrell RP Jr. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide. Cancer Res 1992; 52: 6619-23.
14. Van den Bongard HJGD, Pluim D, van Waardenburg RC, Ravic M, Beijnen JH, Schellens JHM. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anticancer Drugs 2003; 14: 405-10.
15. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
16. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603.
17. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
18. Mainwarning PN, van Cutsem E, van Laethem JL et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil based chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 611.